Evoke Pharma Inc (EVOK)
Official siteDRUG MANUFACTURERS - SPECIALTY & GENERIC
Last updated: Dec 17, 2025 at 4:00 PM ET
Evoke Pharma Inc (EVOK) Financials: Revenue, Profit and Cash Flow
Evoke Pharma reported revenue of $10.25M for the fiscal year ended Dec 31, 2024, up 97.8% from the year before. That year, net income was -$5.35M with a net margin of -52.2%, operating cash flow was -$5.46M and free cash flow was -$5.46M. The quarter ended Sep 30, 2025 had revenue of $4.28M and net income of -$1.16M.
Revenue and Margins
The operating margin was -50.8% in the fiscal year ended Dec 2024.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $10.25M | +97.8% | 96.5% | -50.8% | -52.2% |
| Dec 2023 | $5.18M | +106.5% | 96.1% | -143.4% | -150.4% |
| Dec 2022 | $2.51M | +55.0% | 85.2% | -310.4% | -327.8% |
| Dec 2021 | $1.62M | +6929.0% | 79.7% | -503.8% | -527.7% |
| Dec 2020 | $23.02K | N/A | -276.7% | -56678.3% | -57144.5% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
| Dec 2015 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.25M | $5.18M | $2.51M | $1.62M | $23.02K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $356.53K | $201.88K | $370.39K | $328.12K | $86.71K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $9.89M | $4.98M | $2.14M | $1.29M | -$63.69K | $0 | $0 | $0 | $0 | $0 |
| Research and development | $16.32K | $181.91K | $300.79K | $590.48K | $6.55M | $3.42M | $4.10M | $7.14M | $6.95M | $8.15M |
| Operating income | -$5.20M | -$7.43M | -$7.79M | -$8.15M | -$13.05M | -$7.15M | -$8.01M | -$11.23M | -$10.54M | -$11.82M |
| Net income | -$5.35M | -$7.79M | -$8.22M | -$8.54M | -$13.15M | -$7.13M | -$7.57M | -$12.23M | -$10.75M | -$12.12M |
| EBITDA | -$5.20M | -$7.43M | -$7.79M | -$8.15M | -$13.05M | -$7.15M | -$7.58M | N/A | -$10.48M | -$11.82M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.28M | $3.75M | $3.08M | $3.31M | $2.65M | $2.55M | $1.74M | $1.68M | $1.56M | $1.13M | $810.41K | $796.37K |
| Gross profit | $4.18M | $3.58M | $3.04M | $3.19M | $2.55M | $2.51M | $1.64M | $1.62M | $1.53M | $1.07M | $759.82K | $606.28K |
| Operating income | -$1.14M | -$1.56M | -$1.30M | -$1.19M | -$1.29M | -$1.22M | -$1.50M | -$1.89M | -$1.60M | -$1.78M | -$2.16M | -$1.71M |
| Net income | -$1.16M | -$1.57M | -$1.31M | -$1.19M | -$1.31M | -$1.27M | -$1.58M | -$1.99M | -$1.69M | -$1.87M | -$2.24M | -$1.80M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of $5.00M by $8.60M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.52M | $7.07M | $11.85M | $10.57M | $9.43M | $6.40M | $5.66M | $7.94M | $9.29M | $9.53M |
| Current assets | $17.24M | $6.83M | $11.72M | $10.56M | $9.28M | $6.25M | $5.65M | $7.93M | $9.28M | $9.52M |
| Cash and equivalents | $13.60M | $4.74M | $9.84M | $9.14M | $8.07M | $5.66M | $5.32M | $7.68M | $9.01M | $8.69M |
| Total liabilities | $10.48M | $9.65M | $7.77M | $7.02M | $12.65M | $2.02M | $1.63M | $5.78M | $5.51M | $6.07M |
| Short-term debt | $5.00M | $5.00M | $0 | $12.43K | $245.87K | $138.54K | N/A | N/A | N/A | $146.05K |
| Long-term debt | N/A | $0 | $5.00M | $5.00M | $5.00M | $0 | N/A | $0 | $0 | $4.23M |
| Shareholder equity | $7.04M | -$2.58M | $4.08M | $3.56M | -$3.21M | $4.38M | $4.03M | $2.17M | $3.79M | $3.46M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.65M | $16.06M | $16.38M | $17.52M | $14.15M | $12.14M | $12.45M | $7.07M | $7.85M | $8.98M | $10.04M | $11.85M |
| Total liabilities | $12.29M | $11.69M | $10.53M | $10.48M | $9.77M | $9.47M | $8.96M | $9.65M | $8.73M | $8.44M | $7.91M | $7.77M |
| Cash and equivalents | $11.58M | $12.06M | $12.62M | $13.60M | $11.34M | $9.18M | $9.70M | $4.74M | $5.96M | $7.01M | $8.21M | $9.84M |
| Shareholder equity | $3.36M | $4.37M | $5.84M | $7.04M | $4.39M | $2.66M | $3.50M | -$2.58M | -$873.77K | $538.37K | $2.13M | $4.08M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.46M | -$4.98M | -$6.60M | -$12.35M | -$6.63M | -$5.76M | -$6.98M | -$8.72M | -$8.71M | -$10.50M |
| Capital expenditures | $0 | $3 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$5.46M | -$4.98M | -$6.60M | -$12.35M | -$6.63M | -$5.76M | -$6.98M | -$8.72M | -$8.71M | -$10.50M |
| Dividends paid | N/A | N/A | N/A | N/A | $5.10M | N/A | N/A | $0 | $0 | $0 |
| Share repurchases | $426.29K | $119.30K | $0 | $1.30M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing cash flow | $14.32M | -$119.30K | $7.29M | $13.43M | $9.04M | $6.11M | $4.62M | $7.39M | $9.02M | $5.03M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$521.96K | -$565.02K | -$997.51K | -$1.24M | -$818.70K | -$820.62K | -$2.58M | -$1.11M | -$1.04M | -$1.21M | -$1.63M | -$2.51M |
| Capital expenditures | $2 | $0 | $0 | $2 | $5 | $5 | $4 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$521.96K | -$565.02K | -$997.51K | -$1.24M | -$818.70K | -$820.62K | -$2.58M | -$1.11M | -$1.04M | -$1.21M | -$1.63M | -$2.51M |
Frequently Asked Questions About EVOK
What is Evoke Pharma's annual revenue?
Evoke Pharma reported revenue of $10.25M for the fiscal year ended Dec 31, 2024.
How fast is Evoke Pharma's revenue growing?
Revenue was up 97.8% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 85.0%.
Is Evoke Pharma profitable?
No. Evoke Pharma reported net income of -$5.35M for the fiscal year ended Dec 31, 2024, with a net margin of -52.2%.
How much free cash flow does EVOK generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$5.46M minus capital expenditures of $0 produced free cash flow of -$5.46M.
How much debt does Evoke Pharma have?
The balance sheet dated Dec 31, 2024 reported short-term debt of $5.00M and cash and equivalents of $13.60M.
EVOK pages: Overview, Financials